What to Expect From Viatris' Next Quarterly Earnings Report
/Viatris%20Inc%20logo%20on%20building-by%20SSKH-Pictures%20via%20Shutterstock.jpg)
Valued at a market cap of $10.8 billion, Viatris Inc. (VTRS) is a healthcare company headquartered in Canonsburg, Pennsylvania. It offers a comprehensive portfolio of brand-name, generic, complex generic, and biosimilar medications across a broad range of therapeutic areas. These include non-communicable and infectious diseases, such as cardiovascular conditions, central nervous system (CNS) disorders, dermatology, diabetes, eye care, gastroenterology, immunology, oncology, and respiratory illnesses. It is scheduled to announce its fiscal Q2 earnings for 2025 before the market opens on Thursday, Aug. 7.
Before this event, analysts project this healthcare company to report a profit of $0.56 per share, down 18.8% from $0.69 per share in the year-ago quarter. The company has surpassed Wall Street’s bottom-line estimates in three of the last four quarters, while missing on another occasion. Its earnings of $0.50 per share in the previous quarter outpaced the consensus estimates by 2%.
For the full year, analysts expect VTRS to report EPS of $2.25, down 15.1% from $2.65 per share in fiscal 2024. Nonetheless, its EPS is expected to grow by 7.6% year-over-year to $2.42 in fiscal 2026.
Viatris has declined 20.8% over the past 52 weeks, lagging behind both the S&P 500 Index's ($SPX) 13.4% uptick and the Health Care Select Sector SPDR Fund’s (XLV) 10.2% drop over the same time frame.
On May 8, shares of Viatris gained 5.7% after its better-than-expected Q1 earnings release. Its total revenue declined 11.2% year-over-year to $3.3 billion, but topped the consensus estimates by a slight margin. Moreover, while the company’s adjusted EPS of $0.50 fell 25.4% from the year-ago quarter, it came in 2% above the analyst expectations.
Wall Street analysts are cautious about VTRS’ stock, with an overall "Hold" rating. Among seven analysts covering the stock, one recommends a "Strong Buy," five indicate "Hold," and one suggests a "Moderate Sell” rating. The mean price target for Viatris is $11.18, representing a 21% premium over current levels.
On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.